LAMOTRIGINE FOR THE TREATMENT OF EPILEPSY IN CHILDHOOD

被引:135
作者
BESAG, FMC
WALLACE, SJ
DULAC, O
ALVING, J
SPENCER, SC
HOSKING, G
机构
[1] CTR EPILEPSY, LONDON, ENGLAND
[2] UNIV WALES HOSP, DEPT PAEDIAT, CARDIFF CF4 4XW, S GLAM, WALES
[3] HOP ST VINCENT DE PAUL, SERV NEUROPEDIAT, F-75674 PARIS, FRANCE
[4] DIANALUND EPILEPSY HOSP, DIANALUND, DENMARK
[5] WELLCOME FDN LTD, DEPT CLIN NEUROL & PSYCHIAT, BECKENHAM, KENT, ENGLAND
关键词
D O I
10.1016/S0022-3476(95)70047-1
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: In this multicenter study, the efficacy and tolerability of lamotrigine were assessed in 285 children less than 13 years of age, recruited from 37 centers in 11 countries. Methods: Pooled data from five open add-on studies have been analyzed. All the children had treatment- resistant epilepsy and most had two or more seizure types. Seizure frequency and global evaluation were assessed at the end of four successive 12-week periods of therapy. Results: Seizure frequency was reduced by 50% or more in one third of the patients. Lamotrigine was effective in all seizure types examined, particularly for typical and atypical absence seizures. Atonic seizures also responded well. Improvement was well maintained during the treatment period. The maintenance dose had to be adjusted according to concomitant medication; dose ranges were 1 to 5 mg/kg per day for children taking valproate and 5 to 15 mg/kg per day for those not taking valproate, The commonest reported adverse experiences were somnolence, rash, vomiting, and seizure exacerbations. Adverse experiences led to withdrawal of treatment from 36 patients (12.6%). Conclusions: These results indicate that lamotrigine is well tolerated and is effective for a broad range of seizure types, especially absence seizures and atonic seizures.
引用
收藏
页码:991 / 997
页数:7
相关论文
共 12 条
  • [1] COTARIU D, 1988, CLIN CHEM, V34, P890
  • [2] DAVIES G, 1992, 1992 ANN M AM EP SOC
  • [3] GIBBS J, 1992, DEV MED CHILD NEUROL, V34, P368
  • [4] LAMOTRIGINE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL EFFICACY IN EPILEPSY
    GOA, KL
    ROSS, SR
    CHRISP, P
    [J]. DRUGS, 1993, 46 (01) : 152 - 176
  • [5] CLINICAL SIDE-EFFECTS OF PHENOBARBITAL, PRIMIDONE, PHENYTOIN, CARBAMAZEPINE, AND VALPROATE DURING MONOTHERAPY IN CHILDREN
    HERRANZ, JL
    ARMIJO, JA
    ARTEAGA, R
    [J]. EPILEPSIA, 1988, 29 (06) : 794 - 804
  • [6] HEPATOTOXIC REACTIONS ASSOCIATED WITH CARBAMAZEPINE THERAPY
    HOROWITZ, S
    PATWARDHAN, R
    MARCUS, E
    [J]. EPILEPSIA, 1988, 29 (02) : 149 - 154
  • [7] PRUITT AW, 1985, PEDIATRICS, V76, P644
  • [8] LAMOTRIGINE CLINICAL PHARMACOKINETICS
    RAMBECK, B
    WOLF, P
    [J]. CLINICAL PHARMACOKINETICS, 1993, 25 (06) : 433 - 443
  • [9] LAMOTRIGINE IN TREATMENT OF 120 CHILDREN WITH EPILEPSY
    SCHLUMBERGER, E
    CHAVEZ, F
    PALACIOS, L
    REY, E
    PAJOT, N
    DULAC, O
    [J]. EPILEPSIA, 1994, 35 (02) : 359 - 367
  • [10] ADVERSE-EFFECTS OF VALPROATE
    SCHMIDT, D
    [J]. EPILEPSIA, 1984, 25 : S44 - S49